{"id":"max-40279-01-and-toripalimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Toripalimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade releases the brake on anti-tumor immunity, restoring T cell activation, proliferation, and cytotoxic function against malignant cells. The drug is used in various solid tumors where PD-L1 expression correlates with response.","oneSentence":"Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:30:01.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nasopharyngeal carcinoma"},{"name":"Non-small cell lung cancer"},{"name":"Melanoma"},{"name":"Esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05369286","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Maxinovel Pty., Ltd.","startDate":"2022-04-11","conditions":"Solid Tumor","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20100917","type":"ORIG","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20140103","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20200820","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20021104","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19890720","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20020308","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19881031","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19971029","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19880706","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19910705","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20150511","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20161025","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20020308","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19890720","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20000310","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19911009","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19741017","type":"ORIG","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19900119","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20140619","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"20250711","type":"SUPPL","sponsor":"IMPAX LABS","applicationNumber":"ANDA080767"},{"date":"19990406","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19810828","type":"ORIG","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20001128","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19880726","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20000403","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20150716","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20251222","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20161121","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20150903","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20111201","type":"ORIG","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20140818","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20231215","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20130611","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20191007","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20161216","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"NDA200403"},{"date":"20130129","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20010529","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20000707","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"19920224","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"19870423","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"19851218","type":"ORIG","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20011011","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20140911","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20010606","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"19940511","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"},{"date":"20101101","type":"SUPPL","sponsor":"PLIVA","applicationNumber":"ANDA089097"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"\"MAX-40279-01\" and \"Toripalimab\"","genericName":"\"MAX-40279-01\" and \"Toripalimab\"","companyName":"Maxinovel Pty., Ltd.","companyId":"maxinovel-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Nasopharyngeal carcinoma, Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}